Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

han 35 kg/m2. It is estimated that approximately two-thirds of patients with type 2 diabetes are overweight or obese, with a BMI less than 35 kg/m2. In addition, approximately three-quarters of individuals with BMI less than 35 kg/m2 without type 2 diabetes have dyslipidemia and/or hypertension.

Amylin's Approach to Obesity Research and Development

Currently, physicians and patients seeking prescription medications for weight loss have limited therapeutic options. New scientific advances have established the key role of neurohormones in the physiological regulation of appetite and energy balance, as well as the importance of studying the interaction among these hormones (within the brain) to uncover their full therapeutic potential. Amylin scientists discovered that combination treatment with neurohormones, such as amylin and leptin, can produce additive and synergistic weight loss in animal models. These findings formed the basis for Amylin's innovative integrated neurohormonal approach to the development of obesity treatments.

About Pramlintide/Metreleptin Combination Treatment

Pramlintide acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations. To date, approximately 8,000 individuals have received pramlintide in clinical trials, including more than 950 in obesity studies. Metreleptin (methionyl recombinant leptin; r-metHuLeptin) is an analog of human leptin, a neurohormone secreted by fat cells that plays a fundamental role in the regulation of energy metabolism and body weight. To date, more than 1,200 overweight or obese individuals have received metreleptin in clinical trials, several of which were 16 weeks or longer in duration. In an initial 24-week, Phase 2 clinical proof-of-concept study in 177 overweight or obese individuals (baseline
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is ... services. The core expertise of PRC Clinical is focused on Clinical Trial Management, ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... is making good progress in evaluating the full range of capabilities of its ... Adult tissue stem cells perform the day-to-day renewal and repair of normal tissues ...
(Date:7/28/2015)... ... ... Xsample 530 sample changer for vials can be used with Anton Paar density meters, ... 12,000 mPas (internal air) up to 36,000 (external air) – and can process up to ... 530 is its removable magazine, which is easily lifted off its hub and carried by ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... MIT scientists explaining how they recently discovered a catalyst ... assistance of a five-year $20 million award from the ... (Caltech) Chemical Bonding Center (CBC) project, called "Powering the ... fulfill its goal of efficiently and economically converting solar ...
... MEDX ) announced today that it is scheduled to ... a.m. Eastern Time on,Thursday, September 4, 2008. The event ... Investor Relations section of the Medarex website at, http://www.medarex.com ... available,following the event., About Medarex, Medarex is ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... company producing external use,over-the-counter drugs in the People,s Republic ... to list its common stock on the,NASDAQ Global Market., ... the NASDAQ Global Market on,September 15, 2008, and that ...
Cached Biology Technology:Understanding the science of solar-based energy: more researchers are better than one 2Medarex to Present at the Thomas Weisel Partners Healthcare Conference 2China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market 2China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market 3
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... bacterium that grows in the soil of potato fields can ... a common powerful pesticide used for killing worms on potatoes, ... but lucky for the environment because University of North Carolina ... particular enzyme weren't there, it would take 10,000 years for ...
... come to mind. But they are not the only kind ... as its popular cousin yet its grave situation continues to ... , Sanchez-Azofeifa is the director of the newly ... in the Faculty of Science. The Inter American Institute for ...
... homes and offices is an unaccomplished dream due to the ... The study of photosynthesis in plants could provide new clues ... reaching them, and how they transform it into other forms ... the Freie Universität Berlin, used the X-ray source of the ...
Cached Biology News:New discovery: If it weren't for this enzyme, decomposing pesticide would take millennia 2New discovery: If it weren't for this enzyme, decomposing pesticide would take millennia 3Tropical dry forests receive international recognition 2Plants reveal a secret and bring researchers nearer a cleaner future 2
Request Info...
... Tissue Array (MSTA) slides were designed to study ... from multiple species. Tissue slices from three ... which can then be treated as a single ... in situ hybridization. This format allows ...
... Xcell eukaryotic system, 100 to ... used for electroporation of mammalian ... main unit, CE module for ... square-wave pulses, ShockPod shocking chamber, ...
Request Info...
Biology Products: